Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Oxcarbazepine · 1 trial · 1 indication
CSF obtained from lumbar punctures will be used to determine neurofilament light chain levels from baseline to 48 weeks between the active and placebo treated arms.
| Arm | Type | Description |
|---|---|---|
| OxCarbazepine Treatment | EXPERIMENTAL | Treated for 48 weeks with OxCarbazepine 150mg twice a day alongside current DMDs. |
| OxCarbazepine Placebo | PLACEBO_COMPARATOR | Treated for 48 weeks with matched placebo 1 tablet twice a day alongside current DMDs |
| Name | Type | Description |
|---|---|---|
| Oxcarbazepine | DRUG | Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%. |
| Placebo | DRUG | Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%. |
Inclusion Criteria: * A diagnosis of definite multiple sclerosis * Treatment with DMDs for at least 6 months prior to baseline visit\* * CSF NFL level ≥ 0.380ng/mL * EDSS score between 3.5 and 6.0 * No history of relapses in the 6 months prior to the baseline visit * A history of slow progression o...
Oxcarbazepine is being studied for its protective role in Multiple Sclerosis. It is an investigational small molecule in Phase 2 clinical development for this condition. The drug is being evaluated in a randomized, double-blind, placebo-controlled trial to assess its potential effects in patients with Multiple Sclerosis.
Oxcarbazepine is being developed by National Healthcare Corp. (ticker: NHC). The company is conducting clinical research on this small molecule for the treatment of Multiple Sclerosis, a neurological condition. The drug is currently in Phase 2 development.
Oxcarbazepine is in Phase 2 clinical development for Multiple Sclerosis. It is an investigational drug, not yet approved, and is being studied in a completed clinical trial. The trial was a randomized, double-blind, placebo-controlled study with 30 participants.
Oxcarbazepine has one completed clinical trial for Multiple Sclerosis, registered as NCT02104661, titled "Protective Role of Oxcarbazepine in Multiple Sclerosis." This Phase 2 study enrolled 30 participants in the United Kingdom and was randomized, double-blind, and placebo-controlled.
Oxcarbazepine is not FDA approved for Multiple Sclerosis. It is an investigational drug currently in Phase 2 clinical development for this indication. The drug has completed one clinical trial, but it remains under investigation and has not received regulatory approval for this use.
The clinical study for Oxcarbazepine in Multiple Sclerosis was a Phase 2, randomized, double-blind, placebo-controlled trial. It enrolled 30 adult participants in the United Kingdom and was biomarker-selected. The trial has been completed, and its results have not been disclosed.